Healthcare
Stemcell Holdings, Inc.(STMM)
Live Price
Offline$0.06
-0.00% today
Window Change
+0.00%
Window
Jun 20, 2025 → Apr 6, 2026
- Market Cap
- $1.64M
- Revenue Growth
- +85.1%
- EPS Growth
- +71.9%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 199 bars · Jun 20, 2025 → Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stemcell Holdings, Inc. (STMM) is a Healthcare stock with a market cap of $1.64M and listed on OTC. The stock last traded around $0.06 and up 0.0% across the available one-year price window (Jun 20, 2025 → Apr 6, 2026). Baseline metrics include revenue growth of +85.1%, EPS growth of +71.9%, a dividend yield of 0.0%. What stands out right now is revenue +85.1%, EPS +71.9%, free cash flow -31.7% with operating margin 58.3% and ROIC 63.3%. Valuation is more restrained than many high-expectation growth names at P/E 0.7 and price/sales 0.3. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines STMM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+85.1% vs +7.6% peer median
Operating Margin
Above sector median
+58.3% vs +19.4% peer median
P/E
Below sector median
0.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +85.1% and EPS at +71.9%, with operating margin around 58.3%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STMM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STMM Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STMM and SPY.
Company Overview
Stemcell Holdings, Inc.
Other OTC
Stemcell Holdings, Inc., through its subsidiary, Stemcell Co., Ltd., engages in the regenerative medicine-related business. It provides technical assistance services to the culturing, storing, and delivery of stem cells; and administrative and consulting services to clinics. The company offers two different options for stem cell regenerative therapy, including autologous adipose derived mesenchymal stem cells and natural killer cells. It also provides coordination services to facilitate its stem cell culturing business, which comprise the introduction of patients to clinics, arranging patients' schedules, and translating between patients and clinics due to language barriers. In addition, Stemcell Holdings, Inc. offers Internet marketing services through search engine optimization for clinics; and property and equipment rental services. The company was formerly known as Perfect Acquisition, Inc., and changed its name to Stemcell Holdings, Inc. in January 2016. Stemcell Holdings, Inc. was founded in 2015 and is based in Tokyo, Japan. as of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.
- Leadership
- Takaaki Matsuoka
- IPO Date
- Jul 15, 2020
- Employees
- 28
- Street Address
- 5-9-15-3F, Minamiaoyama
- Mailing
- Tokyo, 107-0062
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 3400 0077
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 0.7
- EV/EBITDA
- —
- Price/Sales
- 0.3
- Price/Book
- 0.4
Growth
- Revenue
- +85.1%
- EPS
- +71.9%
- Free Cash Flow
- -31.7%
Profitability
- Gross Margin
- 80.8%
- Operating Margin
- 58.3%
- Net Margin
- 39.0%
- ROE
- 93.2%
- ROIC
- 63.3%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 2.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.